Browse > Article

Enhancement of Sensitivity of Human Lung Cancer Cell Line to TRAIL and Gefitinib by IGF-1R Blockade  

Lee, Yoon-Jin (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital)
Park, Mi-Young (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital)
Kang, Young-Ae (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital)
Kwon, Sung-Youn (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital)
Yoon, Ho-Il (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital)
Lee, Jae-Ho (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital)
Lee, Choon-Taek (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital)
Publication Information
Tuberculosis and Respiratory Diseases / v.63, no.1, 2007 , pp. 42-51 More about this Journal
Abstract
Background: TRAIL is a cytokine that selectively induces apoptosis in various cancer cell lines. Gefitinib is new targeted drug applied in lung cancer that selectively inhibits EGFR tyrosine kinase. However, lung cancers have shown an initial or acquired resistance to these drugs. This study examined the effect of IGF-1R and its blockade on enhancing the sensitivity of lung cancer cell lines to TRAIL and gefitinib. Methods: Two lung cancer cell lines were used in this study. NCI H460 is very sensitive to TRAIL and gefitinib. On the other hand, A549 shows moderate resistance to TRAIL and gefitinib. The IGF-1R blockade was performed using adenoviruses expressing the dominant negative IGF-1R and shRNA to IGF-1R and AG1024 (IGF-1R tyrosine kinase inhibitor). Results: The adenovirus expressing dominant negative IGF-1R(950st) induced the increased expression of defective IGF-1R on the lung cancer cell surface, and the adenovirus-shIGF-1R effectively decreased the level of IGF-1R expression on cell surface. The genetic blockade of IGF-1R by the adenovirus-dnIGF-1R and AG1024 increased the sensitivity of A549 cells to TRAIL. The reduction of IGF-1R by transduction with ad-shIGF-1R also increased the sensitivity of the A549 cells to gefitinib. Conclusion: The blockade of IGF-1R through various mechanisms increased the sensitivity of the lung cancer cell line that was resistant to TRAIL and gefitinib. However, further studies using other cell lines showing acquired resistance as well as in vivo animal experiments will be needed.
Keywords
TRAIL; Gefitinib; IGF-1R; Lung cancer;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8   DOI   ScienceOn
2 Herbst RS, Maddox AM, Rothenberg ML, Small EJ. Ruhin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-26   DOI   ScienceOn
3 Lee DH, Han JY, Kim HT, Lee JS. Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients, Lung Cancer 2003;53:339-45
4 Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor' mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-601   DOI   ScienceOn
5 Lee CT, Wu S, Gabrilovich D, Chen H, Nadaf-Rahrov S, Ciernik IF, et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer eel] lines. Cancer Res 1996;56:3038-41
6 Cheng J, Hylander BL, Baer MR, Chen X, Repasky EA. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 2006;5:1844-53   DOI   ScienceOn
7 Lee SH, Shin MS, Kim HS, Lee HK, Park WS. Kim SY, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers, Cancer Res 1999;59:5683-6
8 Lee CT, Adachi Y, Carbone DP. IGF-1R blockade strategies in human cancers, Gene Ther Mol Biol 2005;9:77-88
9 Lee CT, Park KH, Adachi Y, Secl JY, Yoo CG, Kim YW, et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate anti tumor effects on lung Cancer, Cancer Gene Ther 2003;10:57-63   DOI   ScienceOn
10 Adachi Y, Lee CT, Carbone DP. Genetic blockade of the Insulin-like growth factor 1 receptor for human malignancy. Novartis Found Symp 2004;262:177-89   DOI
11 Lee YJ, Imsumran A, Park MY, Kwon SY, Yoon HI, Lee JH, et al. Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway. Lung Cancer 2007;55:279-86   DOI   ScienceOn
12 Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M. Chauhan D, et al. Activation of NF-kappaB and upregulation of intracellular antiapoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673-83   DOI   ScienceOn
13 Fire A, Xu S, Montgornery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature 1998;391:806-11   DOI   ScienceOn
14 Min Y, Adachi Y, Yamamoto H, Ito H, Itoh F, Lee CT, et al. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res 2003;63:6432-41
15 Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41   DOI   ScienceOn
16 Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ. Inhibition of the NF- $\kappa$B pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 2004;11:681-90   DOI   ScienceOn
17 Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002;123:1191-204   DOI   ScienceOn
18 Seol JY, Park KH, Hwang CI, Park WY, Yoo CG, Kim YW, et aI. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther 2006;10:540-8   DOI   ScienceOn
19 Lynch TJ, Bell DW, Sordella R, Curubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39   DOI   ScienceOn
20 Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ, Barbu V, Fartoux L, Poupon R, et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib, Int J Cancer 2006;119:2557-66   DOI   ScienceOn
21 Brooks AD, Sayers TJ. Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother 2005;54:499-506   DOI   ScienceOn
22 Poulaki V, Mitsiades CS, Kotoula V, TseleniBalafouta S, Ashkenazi A, Koutras DA, et al. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 2002;161:643-54   DOI   ScienceOn
23 Lee CT, Carbone DP. Chapter 52. Gene Therapy. In; Pass HI, Carbone DP, Johnson DH, Minna JD, Turrisi AT, editors. Lung Cancer, Philadelphia: Lippincott Williams & Wilkins; 2005. p.734-53
24 Griffith TS, Lynch DH TRAIL a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998;10:559-63   DOI   ScienceOn
25 Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37   DOI   ScienceOn
26 Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD, et al. The role of NF-kappa B in TNF- related apoptosis- inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Imrnunol 2001;166:5337-45
27 Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-606   DOI
28 Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ. Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 2004;11:681-90   DOI   ScienceOn
29 Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007;13:2795-803   DOI   ScienceOn
30 Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast Cancer cells. Breast Cancer Res 2005;7:R570-9   DOI
31 Parrizas M Gazit A, Levitzki A, Wertheimer E, LeRoith D. Specific inhibition of insulin-like growth factor-l and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 1997;138:1427-33   DOI   ScienceOn
32 Herbst RS, Ciaecone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-- INTACT 2. J Clin Oneol 2004;99:785-94
33 Jones HE, Goddard L, Gee JM. Hiscox S, Rubini M Barrow D, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinih (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004;11:793-814   DOI   ScienceOn